A large real-world study examines outcomes and treatment patterns among patients with non-muscle-invasive bladder cancer treated with BCG.

NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...

As new therapies emerge, particularly for non-muscle invasive disease, clinicians and patients are faced with increasingly ...

Jimi Stewart, a rollerblading enthusiast from Austin, Texas, was diagnosed with a type of non-muscle invasive bladder cancer ...

( NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced it will present new treatment comparison results evaluating ANKTIVA ® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...

ImmunityBio will present new findings on its Anktiva immunotherapy combined with BCG for non-muscle-invasive bladder cancer ...

Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...

But when Jimi began experiencing bladder cancer symptoms, including blood in his urine, he felt a different kind of rush. It ...

Inlexzo is an intravesical gemcitabine releasing system that is inserted directly into the bladder through a urinary catheter. The Food and Drug Administration (FDA) has approved Inlexzo ™ ...

A new study suggests that a urine-based biomarker test shows promise in forecasting bladder cancer treatment response, which ...

LAS VEGAS -- Patients with high-risk, treatment-unresponsive non-muscle invasive bladder cancer (NMIBC) had an unprecedented response rate and disease-free survival (DFS) with an investigational ...